Telehealth-Delivered Cognitive Behavioral Therapy for Insomnia in Individuals with Multiple Sclerosis: A Pilot Study.

IF 2.2 Q3 CLINICAL NEUROLOGY
Multiple Sclerosis International Pub Date : 2022-03-02 eCollection Date: 2022-01-01 DOI:10.1155/2022/7110582
David Turkowitch, Rebecca Ludwig, Eryen Nelson, Michelle Drerup, Catherine F Siengsukon
{"title":"Telehealth-Delivered Cognitive Behavioral Therapy for Insomnia in Individuals with Multiple Sclerosis: A Pilot Study.","authors":"David Turkowitch, Rebecca Ludwig, Eryen Nelson, Michelle Drerup, Catherine F Siengsukon","doi":"10.1155/2022/7110582","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Over 50% of individuals with multiple sclerosis (MS) have moderate or severe sleep disturbances, insomnia being the most common. In-person cognitive behavioral therapy for insomnia (F2F-CBTi) is currently the first-line treatment for insomnia. However, given potential limitations to access including mobility difficulty, fatigue, or living in a rural area, telehealth-delivered CBT-I (tele-CBTi) has been considered as an alternative treatment. The purpose of this study was to assess the feasibility and treatment effect of tele-CBTi in people with MS and compare it to outcomes from a F2F-CBTi study in individuals with MS.</p><p><strong>Methods: </strong>11 individuals with MS and symptoms of insomnia participated in 6 weekly CBT-I sessions with a trained CBT-I provider via live video. Insomnia severity (ISI), sleep quality (PSQI), and fatigue severity (FSS and MFIS) were assessed pre- and posttreatment as primary outcomes. Sleep onset latency (SOL), sleep efficiency (SE) and total sleep time (TST) from the PSQI, depression (PHQ-9), anxiety (GAD-7), sleep self-efficacy (SSES), and quality of life (MSIS-29) were also assessed pre- and posttreatment as secondary outcomes.</p><p><strong>Results: </strong>Participants resided in 9 different states. Retention and adherence rates were 100%. There were significant improvements in ISI, PSQI, MFIS, FSS, SOL, SSES, PHQ-9, and MSIS-29, but not SE, TST, or GAD-7. There were no significant differences between the F2F-CBTi group and tele-CBTi group for magnitude of change in the primary outcomes (ISI, PSQI, MFIS, and FSS) or the secondary outcomes (SOL, SE, TST, SSES, PHQ-9, GAD-7, and MSIS-29).</p><p><strong>Conclusions: </strong>Tele-CBTi is feasible and has outcome measures that are similar to that of in-person CBT-I treatment. Tele-CBTi may increase access to insomnia treatment in individuals with MS.</p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2022-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906967/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2022/7110582","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Over 50% of individuals with multiple sclerosis (MS) have moderate or severe sleep disturbances, insomnia being the most common. In-person cognitive behavioral therapy for insomnia (F2F-CBTi) is currently the first-line treatment for insomnia. However, given potential limitations to access including mobility difficulty, fatigue, or living in a rural area, telehealth-delivered CBT-I (tele-CBTi) has been considered as an alternative treatment. The purpose of this study was to assess the feasibility and treatment effect of tele-CBTi in people with MS and compare it to outcomes from a F2F-CBTi study in individuals with MS.

Methods: 11 individuals with MS and symptoms of insomnia participated in 6 weekly CBT-I sessions with a trained CBT-I provider via live video. Insomnia severity (ISI), sleep quality (PSQI), and fatigue severity (FSS and MFIS) were assessed pre- and posttreatment as primary outcomes. Sleep onset latency (SOL), sleep efficiency (SE) and total sleep time (TST) from the PSQI, depression (PHQ-9), anxiety (GAD-7), sleep self-efficacy (SSES), and quality of life (MSIS-29) were also assessed pre- and posttreatment as secondary outcomes.

Results: Participants resided in 9 different states. Retention and adherence rates were 100%. There were significant improvements in ISI, PSQI, MFIS, FSS, SOL, SSES, PHQ-9, and MSIS-29, but not SE, TST, or GAD-7. There were no significant differences between the F2F-CBTi group and tele-CBTi group for magnitude of change in the primary outcomes (ISI, PSQI, MFIS, and FSS) or the secondary outcomes (SOL, SE, TST, SSES, PHQ-9, GAD-7, and MSIS-29).

Conclusions: Tele-CBTi is feasible and has outcome measures that are similar to that of in-person CBT-I treatment. Tele-CBTi may increase access to insomnia treatment in individuals with MS.

针对多发性硬化症患者失眠症的远程医疗认知行为疗法:试点研究
背景:50%以上的多发性硬化症(MS)患者有中度或严重的睡眠障碍,其中最常见的是失眠。面对面失眠认知行为疗法(F2F-CBTi)是目前治疗失眠的一线疗法。然而,考虑到行动不便、疲劳或居住在农村地区等潜在的治疗限制,远程医疗认知行为疗法(tele-CBTi)被认为是一种替代疗法。本研究旨在评估远程 CBTi 在多发性硬化症患者中的可行性和治疗效果,并将其与针对多发性硬化症患者的 F2F-CBTi 研究结果进行比较。失眠严重程度(ISI)、睡眠质量(PSQI)和疲劳严重程度(FSS 和 MFIS)作为主要结果在治疗前和治疗后进行评估。作为次要结果,还对 PSQI 的睡眠开始潜伏期(SOL)、睡眠效率(SE)和总睡眠时间(TST)、抑郁(PHQ-9)、焦虑(GAD-7)、睡眠自我效能(SSES)和生活质量(MSIS-29)进行了治疗前后的评估:参与者居住在 9 个不同的州。保留率和坚持率均为 100%。ISI、PSQI、MFIS、FSS、SOL、SSES、PHQ-9 和 MSIS-29 有明显改善,但 SE、TST 或 GAD-7 没有明显改善。F2F-CBTi组与远程CBTi组在主要结果(ISI、PSQI、MFIS和FSS)或次要结果(SOL、SE、TST、SSES、PHQ-9、GAD-7和MSIS-29)的变化幅度上没有明显差异:结论:远程 CBTi 是可行的,其结果测量与面对面 CBT-I 治疗相似。远程 CBTi 可以增加多发性硬化症患者接受失眠治疗的机会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Multiple Sclerosis International
Multiple Sclerosis International CLINICAL NEUROLOGY-
自引率
0.00%
发文量
6
审稿时长
15 weeks
期刊介绍: Multiple Sclerosis International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to all aspects of multiple sclerosis, including clinical neurology, neuroimaging, neuropathology, therapeutics, genetics, neuroimmunology, biomarkers, psychology and neurorehabilitation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信